{"id":1683,"date":"2026-05-31T14:32:16","date_gmt":"2026-05-31T14:32:16","guid":{"rendered":"https:\/\/one-peptides.com\/semaglutide-vs-retatrutide-comparison-of-mechanisms-and-clinical-outcomes\/"},"modified":"2026-10-04T10:29:05","modified_gmt":"2026-10-04T10:29:05","slug":"semaglutide-vs-retatrutide-comparison-of-mechanisms-and-clinical-outcomes","status":"publish","type":"post","link":"https:\/\/one-peptides.com\/de\/semaglutide-vs-retatrutide-comparison-of-mechanisms-and-clinical-outcomes\/","title":{"rendered":"Semaglutide vs Retatrutide – comparison of mechanisms and clinical outcomes"},"content":{"rendered":"
\n\tHome<\/a>\n<\/span>\u00bb<\/span>\n\tMetabolic research<\/a>\n<\/span>\u00bb<\/span>\n\tSemaglutide vs Retatrutide \u2013 comparison of mechanisms and clinical outcomes\n<\/span><\/div><\/div>\n

Two peptides from the same broad pharmacological class – incretin agonists<\/a> \u2014 but two completely different philosophies of molecule design. Semaglutide, developed by Denmark’s Novo Nordisk and launched in 2017, is a GLP-1 receptor monoagonist – a continuation of the lineage previously started by liraglutide, exenatide and lixisenatide. The design assumption was conservative: take a proven mechanism (activation of one incretin receptor), improve the pharmacokinetics through structural modifications, obtain the most effective GLP-1RA available on the market.<\/p>\n

Retatrutide, developed by the American Eli Lilly and currently in phase III clinical trials, represents a different – radical philosophy. The molecule activates not one but Three<\/strong> hormonal receptors simultaneously: GLP-1, GIP and glucagon. The design assumption was ambitious: instead of perfecting monoagonism, open a new therapeutic category through the coordinated activity of three complementary metabolic pathways.<\/p>\n

This article compares both peptides along five axes: origin and class, structure and mechanism, clinical outcomes, safety profile, regulatory status. The idea is to give an idea of the differences – not to suggest that one peptide is “better”. Each axis shows compromises and specific applications.<\/p>\n

\n

\ud83d\udcd6 The following article is educational and is a review of published scientific literature about semaglutide and retatrutide. The text does not constitute medical advice. Semaglutide is an EMA and FDA registered drug – it requires a prescription. Retatrutide is in Phase III clinical trials – at the time of writing it is not approved. Peptides from the One Peptides catalog are intended only for laboratory tests (Research Use Only).<\/p>\n<\/blockquote>\n

Origin and pharmacological class<\/h2>\n

Semaglutide<\/h3>\n

Semaglutide (Novo Nordisk internal designation: NN9535) is a GLP-1 receptor monoagonist. First phase I clinical trial – 2008. First registration as a drug (Ozempic, type 2 diabetes) – 2017 (FDA). Manufacturer: Novo Nordisk (Denmark).<\/p>\n

Retatrutide<\/h3>\n

Retatrutide (Eli Lilly internal designation: LY3437943) is a triple agonist of GLP-1, GIP and glucagon receptors (GLP-1R\/GIPR\/GCGR). First phase I clinical trial – 2020. Status (2026): in phase III clinical trials in the TRIUMPH program. Producer: Eli Lilly (USA).<\/p>\n

The informal shorthand used for retatrutide in online searches is explained in a separate entry: the informal name \u201creta\u201d<\/a>.<\/p>\n

Table: origin and class<\/h3>\n\n\n\n\n<\/colgroup>\n\n\n\n\n\n\n\n\n\n
Characteristic<\/strong><\/th>\nSemaglutide<\/strong><\/th>\nRetatrutide<\/strong><\/th>\n<\/tr>\n
Producer<\/td>\nNovo Nordisk (Denmark)<\/td>\nEli Lilly (USA)<\/td>\n<\/tr>\n
Internal marking<\/td>\nNN9535<\/td>\nLY3437943<\/td>\n<\/tr>\n
Pharmacological class<\/td>\nGLP-1R monoagonist<\/td>\nGLP-1R\/GIPR\/GCGR triple agonist<\/td>\n<\/tr>\n
First phase I<\/td>\n2008<\/td>\n2020<\/td>\n<\/tr>\n
First registration<\/td>\n2017 (Ozempic, USA)<\/td>\nnone (phase III ongoing)<\/td>\n<\/tr>\n
Status (2026)<\/td>\nRegistered in 4 indications<\/td>\nPhase III TRIUMPH<\/td>\n<\/tr>\n
Trade brands<\/td>\nOzempic, Wegovy, Rybelsus<\/td>\nlack<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Molecular structure and mechanism of action<\/h2>\n

Semaglutide – structural details<\/h3>\n

The semaglutide sequence is based on human GLP-1 (7-37) with three modifications:<\/p>\n